Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Our investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential to address a variety of IgG-mediated autoimmune diseases as a subcutaneous injection.
We have initiated Phase 2 studies in two target indications: myasthenia gravis (MG) and Graves’ ophthalmopathy (GO). We anticipate that we will submit an IND in one additional indication, warm autoimmune hemolytic anemia (WAIHA), in the second half of 2019. We plan to continue expanding our pipeline with innovative therapies that could transform the lives of patients living with autoimmune diseases.
IMVT-1401 is the result of a multi-year research program by Immunovant’s partner, HanAll Biopharma, to engineer a highly potent FcRn antibody specifically optimized for subcutaneous injection with a small gauge needle.
In a Phase 1 study of healthy volunteers receiving weekly 4 subcutaneous injections, IMVT-1401 delivered a mean IgG reduction of 63% at a dose of 340 mg and delivered a mean IgG reduction of 78% at a dose of 680 mg.
IMVT-1401 was also generally well-tolerated by healthy volunteers following subcutaneous and intravenous administration.
Our Board of Directors
Frank Torti, M.D., M.B.A. has served as Chairperson of Immunovant’s board of directors since June 2019. He has also served as Vant Investment Chair for Roivant Pharma since August 2018. Prior to Roivant, Dr. Torti was at New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today. Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.
Myrtle Potter has served as a member of Immunovant’s board of directors since June 2019. She has also served as Vant Operating Chair for Roivant Pharma since July 2018. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences consulting firm and served as the Chief Executive Officer until she joined Roivant. Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year. Prior to Genentech, she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business and a vice president at Merck & Co. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Rite Aid and Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.